张思龙简介
张思龙,男,1989年11月,武汉大学生物化学与分子生物学博士,一流学科特聘教授A类,硕士生导师,主要从事靶点结构的小分子药物设计、合成及早期成药性评价研究。重点开展了基于外源性机制的蛋白降解剂和小分子靶向抑制剂的研究工作,近三年作为第一作者/通讯作者已发表论文15篇,其中中科院一区文章12篇,包括药化顶级top1 期刊J Med Chem 6 篇。目前主持国家自然科学基金1项。
邮箱:silongzhang@whu.edu.cn
2007年9月-2011年6月,华东理工大学,bv官网-(中国)科技公司,药物制剂,学士;
2013年9月-2015年6月,武汉大学,bv官网-(中国)科技公司,制药工程,硕士。导师:周海兵教授、董春娥教授;
2015年9月-2019年6月,武汉大学,bv官网-(中国)科技公司,生物化学与分子生物学,博士。导师:周海兵教授、董春娥教授;
2016年12月-2018年7月,美国伊利诺伊大学香槟分校(UIUC),访问学者。导师:John Katzenellenbogen 教授 (美国艺术与科学学院院士、入选美国化学会药物化学名人堂);
【学术兼职及荣誉称号】
1. 《Acta Materia Medica》青年编委 |
【主持项目】
1. 国家自然科学基金青年基金项目:单线态氧介导的可控化雌激素受体α光敏降解剂的构建及其抗乳腺癌活性研究,2023/01-2025/12,30万;
2.贵州大学自然科学专项(特岗)科研基金项目:基于化学降解机制的SOS1降解剂的构建、作用媒介的探究及其抗肿瘤活性研究,2023/07-2027/07,80万。
【近期发表论文】
1. He H.; Wang Z. W.; Peng X. K.: Qing L. L.; Zhang Y.; Fu S. J.; Xu J.; Li Y. Y.*; Zhang S.L.*. Identification of a sonically activated degrader of methionine adenosyltransferase 2A by an in silico Approach assisted with the hole−electron analysis. J. Med. Chem. 2024, 67,543-554. (*Corresponding author, IF = 7.3)
2.Xu J.; Zhao A.; Chen D.; Wang J.; Ma J.; Qing L. L.; Li Y. Y.; Fang H. X.; He H.*; Pan W. D.*; Zhang S. L.* Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability. Eur. J. Med. Chem. 2024, 266, 116160. (*Corresponding author, IF = 6.7)
3.Zhang S. L.; Zhang Y.; Wang Z. W.; Qing L. L.; Fu S. J..; Xu J.; Li Y. Y. *; Fang H. X.*; He H.*. Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors. Eur. J. Med. Chem. 2023, 261, 115836. (*Corresponding author, IF = 7.088)
4.Li Y. Y.; Sun M.; Chen X.; Zhang S. L.*; He H.*. Design of sonosensitizers integrated with resveratrol motif for synergetic sonodynamic therapy and NF-κB transcription suppression of breast cancer. J. Med. Chem. 2023, 66, 6149-6159. (*Corresponding author, IF = 8.039)
5.He H.; Chen R. Q.; Wang Z. W.; Qing L. L.; Zhang Y.; Liu Y.; Pan W. D.*; Fang H. X.*; Zhang S. L.*. Design of orally-bioavailable tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR. Bioorg. Chem. 2023, 136, 106536. (*Corresponding author, IF = 5.037)
6.Zhang S. L.; Qing L. L.; Wang Z. W.; Zhang Y.; Li Y. Y.; Fang H. X.*; Liu Y.; He H.*. Design and structural optimization of methionine adenosyltransferase 2A (MAT2A) inhibitors with high in-vivo potency and oral bioavailability. J. Med. Chem. 2023, 66, 4849-4867. (IF = 8.039)
7.Zhang S. L. #*; Li Y. Y.#; Li T.; Zhang Y.; Li H. M.; Cheng Z. Z.; Peng N.; Liu Y.; Xu J. *; He H. * Activable targeted protein degradation platform based on light-triggered singlet oxygen. J. Med. Chem. 2022, 65, 3632-3643. (*Corresponding author, # Co-First Author) (IF = 8.039) 入选全球ESI“高被引论文”
8.Zhang S.L.; Zhang Y.; Chen X.; Xu J.; Fang H. X.; Li Y. Y. *; Liu Y.*; He H.*. Design and Structural Optimization of Orally-Bioavailable SOS1 Inhibitors for the Treatment of KRAS-driven Carcinoma. J. Med. Chem. 2022, 65, 23, 15856-15877. (IF = 8.039)
9.He H.; Zhang Y.; Xu J.; Li Y. Y.; Fang H. X. *; Liu Y. *; Zhang S.L.*. Discovery of orally-bioavailable SOS1 inhibitors for suppressing KRAS-driven carcinoma. J. Med. Chem. 2022, 65, 19, 13158-13171 (*Corresponding author, IF = 8.039)
10.Zhang, Y.; Ding, X.; Xie, F.; Gao, M. J.; Qiu, J. L.; Wang, Z. W.; Qing, L. L.; Yan, J. Q.; Li, Y. Y.; Xu, J.; Jiao, Y. H.;Liu, Y.*; He H.*; Zhang, S. L.* Targeted recruitment and degradation of estrogen receptor α by photothermal polydopamine nanoparticles for breast tumor ablation. Adv. Healthc. Mater. 2022, 11, 2200960. (*Corresponding author, IF = 11.092)
11.Li T.; Zhang Y.; Wang Z. W.; Qing L. L.; Zhang L. J. Peng N.; Liu Y. *; Zhang S. L. *; He H.* AIEgen based turn-on fluorescent probes of histone deacetylase 6 via restriction of molecular motion. Sensor Actuat. B-Chem. 2022, 364, 131882. (*Corresponding author, IF = 9.221)
12.Xu, J.; Feng, Y.; Han, L.; Yi, M.; Jiao, Y. H.; Zhang, S. L.*; He H.* Photoexcited Graphene Oxides Activate Silent Viruses in Bacteria in Dependency on Their Sizes. Environmental Science: Nano. 2022, 9, 3918-3926 (*Corresponding author, IF = 9.473)